Summary
Women in the general population have a 3% and 1.4% risk, respectively, for endometrial and ovarian cancer. Educational efforts should be focused on teaching women to seek medical attention for postmenopausal, irregular, or heavy vaginal bleeding as well as for persistent abdominal symptoms including bloating, increased girth, a change in bowel and bladder habits, or abdominal or pelvic pain. Women in specific high-risk groups, including women taking tamoxifen and obese women, should be counseled regarding their increased risk of endometrial cancer and the signs and symptoms of the disease. Finally, women whose risk of endometrial or ovarian cancer is extremely elevated owing to hereditary predisposition should be counseled about specific chemopreventive and surgical prevention options as well as participation in screening studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214–218.
Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997;277:915–919.
Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89:1765–1772.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676–689.
Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705–2712.
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.
Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998;339:424–428.
Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–1622.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Lu, K.H. (2006). Prevention and Early Detection of Endometrial and Ovarian Cancers. In: Eifel, P.J., Gershenson, D.M., Kavanagh, J.J., Silva, E.G. (eds) Gynecologic Cancer. M. D. Anderson Cancer Care Series, vol 5. Springer, New York, NY. https://doi.org/10.1007/0-387-28796-5_2
Download citation
DOI: https://doi.org/10.1007/0-387-28796-5_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-28794-2
Online ISBN: 978-0-387-28796-6
eBook Packages: MedicineMedicine (R0)